Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03197532 · ClinicalTrials.gov registry record
Assessing Urinary Hormones in Female Cancer Survivors
A clinical trial, sponsored by University of Pennsylvania.
- Completed
- Registry status
- 38
- Enrollment target
NCT03197532: Completed study, sponsored by University of Pennsylvania.
NCT03197532 is a clinical trial that has completed, run by University of Pennsylvania. The registered enrollment target is 38 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03197532 has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- 38 participants
- Enrollment target
Study Summary
Women of late to mid reproductive age may participate in a study using novel methodology to identify subtle changes in the reproductive endocrine axis via daily urine hormone analysis, which may have important implications for reproduction and may signal reproductive senescence.
Primary Outcome
Integrated urinary follicular-phase Follicle Stimulating Hormone (FSH) in urine samples collected daily for 2 menstrual cycles will be measured in mIU/mL by means of two-site chemiluminescent immunoassay with the use of two monoclonal antibodies.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2011-01 |
| Est. Completion | 2016-05 |
What the finished NCT03197532 record still lists
NCT03197532 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 38 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT03197532 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03197532 about?
NCT03197532 is a clinical study titled "Assessing Urinary Hormones in Female Cancer Survivors". Women of late to mid reproductive age may participate in a study using novel methodology to identify subtle changes in the reproductive endocrine axis via daily urine hormone analysis, which may have important implications for reproduction and may signal reproductive senescence.
What is the current status of trial NCT03197532?
This trial is currently completed. The enrollment target is 38 participants. The study started on 2011-01. Estimated completion is 2016-05.
Who is sponsoring clinical trial NCT03197532?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia